C. M. Aboud

Microvascular Outcomes after Metabolic Surgery (MOMS) in patients with type 2 diabetes mellitus and class I obesity: rationale and design for a randomised controlled trial

C. L. le Roux, R. Cohen, T. V. Pereira, 2017, BMJ Open.

Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial.

C. L. le Roux, N. Docherty, R. Cohen, 2020, JAMA surgery.

Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial

C. L. le Roux, A. Miras, Brett Johnson, 2021, Diabetes Care.

Gastric bypass versus best medical treatment for diabetic kidney disease: 5 years follow up of a single-centre open label randomised controlled trial

C. L. le Roux, A. Friedman, R. Cohen, 2022, EClinicalMedicine.

Urinary Metabolomic Changes Accompanying Albuminuria Remission following Gastric Bypass Surgery for Type 2 Diabetic Kidney Disease

C. L. le Roux, D. Malmodin, L. Fändriks, 2022, Metabolites.

Defining Global Benchmarks in Bariatric Surgery: A Retrospective Multicenter Analysis of Minimally Invasive Roux-en-Y Gastric Bypass and Sleeve Gastrectomy.

Andrés San Martín, M. Puhan, D. Raptis, 2019, Annals of surgery.